MCMariia V. Chernysh

Mariia V. Chernysh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mariia V. Chernysh has a total of 40 co-authors. Here are the top co-authors by number of shared publications:

  • Allan V. Kalueff

    Institute of Translational Biomedicine, St. Petersburg State University, 199034 St. Petersburg, Russia

    2 shared publications
  • Anna K. Savva

    Laboratory of Insect Biopharmacology and Immunology, Faculty of Biology, St. Petersburg State University, St. Petersburg, Russia

    2 shared publications
  • Murilo Sander de Abreu

    Graduate Program in Health Sciences, Federal University of Health Sciences of Porto Alegre, Porto Alegre, Brazil

    2 shared publications
  • Tamara G. Amstislavskaya

    Scientific Research Institute of Physiology and Basic Medicine, Novosibirsk, Russia

    2 shared publications
  • Tatyana Strekalova

    I.M. Sechenov First Moscow State Medical University, Moscow, Russia; Maastricht University, Maastricht, the Netherlands; Research Institute of General Pathology and Pathophysiology, Moscow, Russia

    2 shared publications
  • Aleksandr S. Taranov

    Institute of Translational Biomedicine, St. Petersburg State University, St. Petersburg, Russia

    1 shared publication

Latest Publications

  • The zebrafish tail immobilization (ZTI) test as a new tool to assess stress-related behavior and a potential screen for drugs affecting despair-like states

    by Konstantin A. Demin, Anton M. Lakstygal, Maria V. Chernysh, Natalia A. Krotova, Aleksandr S. Taranov, Nikita P. Ilyin, Maria V. Seredinskaya, Natsuki Tagawa, Anna K. Savva, Mikael S. Mor, et al.


  • Open Access

    Immunohistochemical markers for neurobiology

    by Dmitrii E. Korzhevskii, Igor P. Grigor’eV, Valeriia V. Gusel’nIkova, Elena A. Kolos, Elena S. Petrova, Olga V. Kirik, Dina A. Sufieva, Valeriia A. Razenkova, Mariia V. Antipova, Mariia V. Chernysh, et al.

    In neurobiological studies, crucial is the selection of most appropriate and informative experimental methods, one of which is immunohistochemistry. This review briefly summarizes the experience of adaptation of immunohistochemical methods to nervous system studies accumulated over years the Laboratory of Functional Morphology of the Central and Peripheral Nervous System (Institute of Experimental Medicine). The aim of this work was to determine the most effective and reliable immunomarkers for neurobiological studies. The article contains theoretical basis and practical recommendations for use of key cytospecific and functional markers used in studies of structural and functional organization of brain and spinal cord of mammalian animals and human. In particular, the results of immunohistochemical reactions to neural markers (NeuN, neurofilament proteins, alpha-tubulin, alpha-synuclein), neurotransmitter synthesizing enzymes (tyrosine hydroxylase, glutamate decarboxylase, choline acetyltransferase, NO synthase) and glial markers (GFAP, glutamine synthetase, Iba-1, vimentin) are demonstrated. The presented methodology is useful for experimental neurobiology and clinical morphological diagnostics.


  • Animal models of major depressive disorder and the implications for drug discovery and development

    by Konstantin A. Demin, Maxim Sysoev, Maria V. Chernysh, Anna K. Savva, Mamiko Koshiba, Edina A. Wappler-Guzzetta, Cai Song, Murilo S. De Abreu, Brian Leonard, Matthew O. Parker, et al.

    Introduction: Depression is a highly debilitating psychiatric disorder that affects the global population and causes severe disabilities and suicide. Depression pathogenesis remains poorly understood, and the disorder is often treatment-resistant and recurrent, necessitating the development of novel therapies, models and concepts in this field. Areas covered: Animal models are indispensable for translational biological psychiatry, and markedly advance the study of depression. Novel approaches continuously emerge that may help untangle the disorder heterogeneity and unclear categories of disease classification systems. Some of these approaches include widening the spectrum of model species used for translational research, using a broader range of test paradigms, exploring new pathogenic pathways and biomarkers, and focusing more closely on processes beyond neural cells (e.g. glial, inflammatory and metabolic deficits). Expert opinion: Dividing the core symptoms into easily translatable, evolutionarily conserved phenotypes is an effective way to reevaluate current depression modeling. Conceptually novel approaches based on the endophenotype paradigm, cross-species trait genetics and ‘domain interplay concept’, as well as using a wider spectrum of model organisms and target systems will enhance experimental modeling of depression and antidepressant drug discovery.